Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Interventions: DRUG: palbociclib and exemestane plus trastuzumab and pyrotinib
Sponsor: Guangdong Provincial People's Hospital